+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and initial effectiveness of mesenchymal stromal cells MSCs derived from umbilical cord tissue to treat cartilage damage in the knee joint. This prospective, multicenter, single-arm, open-label clinical trial focuses on patients with symptomatic cartilage defects who are candidates for surgical cartilage regeneration. The study aims to provide detailed safety data and early efficacy outcomes over a two-year period following treatment. Eligible patients will undergo arthroscopic or minimally invasive knee surgery during which the investigational product, called MesemCart, containing 10 to 20 million UC-MSCs applied to a collagen carrier, will be placed once directly on the cartilage defect. All participants receive this same treatment and are followed up regularly for 24 months. The study includes a single treatment arm without any placebo or comparison groups. Participants will be monitored through scheduled visits up to two years after surgery to assess safety, including serious adverse events, and to evaluate cartilage regeneration using imaging scores and patient-reported outcomes. These outcomes include pain levels, knee-related quality of life, symptoms, stiffness, activities of daily living, and physical resilience during sports, measured at 12 and 24 months. Safety will be tracked continuously, with all adverse events documented and assessed throughout the study.

Age: 18Years - 60YearsAll GendersPhase 1Phase 2
7 locations
R

Actively Recruiting

Ulcerative colitis UC is an inflammatory bowel disease causing inflammation and bleeding in the rectum and colon. This study evaluates the change in disease activity in adult participants with moderate to severe UC who are treated with risankizumab in real-world clinical practice. The study is observational and will include about 200 participants across multiple sites in Germany and Austria. Participants will receive risankizumab as prescribed by their physicians according to routine clinical care and local guidelines. The treatment is not assigned by the study team but follows the physicians decision. Participants will be observed and followed for up to 52 weeks while receiving this treatment under normal clinical conditions. During the study, participants will attend regular visits at hospitals or clinics as part of their routine care. There will be no additional burden beyond regular clinical visits. Researchers will measure the percentage of participants achieving symptomatic remission based on the Partial Adapted Mayo Score over approximately 52 weeks. Safety and effectiveness of risankizumab will be monitored throughout the study period.

Age: 18Years +All Genders
57 locations